UBS Group
MRNA icon

UBS Group’s Moderna MRNA Stock Holding History

UBS Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.5M Sell
837,300
-4,923,000
-85% -$230M 0.01% 1812
2025
Q4 		$170M Buy
5,760,300
+3,278,000
+132% +$89.1M 0.03% 665
2025
Q3 		$64.1M Sell
2,482,300
-1,164,300
-32% -$32.5M 0.01% 1386
2025
Q2 		$101M Buy
3,646,600
+347,800
+11% +$9.16M 0.02% 952
2025
Q1 		$93.5M Buy
3,298,800
+2,685,500
+438% +$95.3M 0.02% 976
2024
Q4 		$25.5M Sell
613,300
-24,500
-4% -$1.17M ﹤0.01% 2080
2024
Q3 		$42.6M Buy
637,800
+277,000
+77% +$25.4M 0.01% 1264
2024
Q2 		$42.8M Sell
360,800
-17,900
-5% -$2.27M 0.01% 1142
2024
Q1 		$40.4M Sell
378,700
-351,900
-48% -$35.5M 0.01% 1178
2023
Q4 		$72.7M Buy
730,600
+60,200
+9% +$5.06M 0.02% 749
2023
Q3 		$69.2M Buy
670,400
+160,000
+31% +$17.8M 0.02% 657
2023
Q2 		$62M Sell
510,400
-154,900
-23% -$20.7M 0.02% 712
2023
Q1 		$102M Buy
665,300
+380,400
+134% +$62.8M 0.04% 453
2022
Q4 		$51.2M Sell
284,900
-41,900
-13% -$6.85M 0.02% 788
2022
Q3 		$38.6M Buy
326,800
+176,800
+118% +$26.8M 0.02% 836
2022
Q2 		$21.4M Buy
150,000
+80,200
+115% +$11.5M 0.01% 1264
2022
Q1 		$12M Sell
69,800
-133,800
-66% -$22.5M ﹤0.01% 1799
2021
Q4 		$51.7M Sell
203,600
-24,500
-11% -$7.16M 0.01% 940
2021
Q3 		$87.8M Sell
228,100
-46,900
-17% -$17.3M 0.03% 584
2021
Q2 		$64.6M Sell
275,000
-62,100
-18% -$11.1M 0.02% 710
2021
Q1 		$44.1M Buy
337,100
+137,000
+68% +$19.9M 0.01% 915
2020
Q4 		$20.9M Buy
200,100
+184,400
+1,175% +$18.7M 0.01% 1320
2020
Q3 		$1.11M Buy
15,700
+15,600
+15,600% +$1.09M ﹤0.01% 3560
2020
Q2 		$6K Sell
100
-36,400
-100% -$1.99M ﹤0.01% 7302
2020
Q1 		$1.09M Buy
+36,500
New +$840K ﹤0.01% 3274

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's MRNA Position: Q1 2026 in Review

UBS Group increased its Moderna (MRNA) stake by 7.9% in Q1 2026, buying an estimated $15M and bringing the position to 4,407,907 shares worth $224M. The position accounts for 0.03% of the portfolio, ranked #565.

UBS Group first reported a position in MRNA in Q4 2018 and has held it in 30 quarters since. The position peaked at $294M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • UBS Group held 4,407,907 shares of Moderna worth $224M as of Q1 2026.
  • UBS Group bought 321,141 Moderna shares in Q1 2026, an estimated $15M.
  • Moderna made up 0.03% of UBS Group's portfolio in Q1 2026, its #565 holding.
  • UBS Group first reported a position in Moderna in Q4 2018 and has held it in 30 quarters since.
  • UBS Group's Moderna position peaked at $294M in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.